GSA Capital Partners LLP Sells 587,544 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

GSA Capital Partners LLP decreased its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 63.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 345,632 shares of the biopharmaceutical company's stock after selling 587,544 shares during the quarter. GSA Capital Partners LLP owned about 0.17% of Sangamo Therapeutics worth $299,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. State Board of Administration of Florida Retirement System grew its stake in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 23,650 shares in the last quarter. Meritage Portfolio Management grew its position in Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 6,740 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 38,850 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Sangamo Therapeutics during the second quarter valued at approximately $67,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Sangamo Therapeutics during the second quarter valued at approximately $89,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on SGMO. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, November 14th. Barclays lifted their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. Finally, StockNews.com raised shares of Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, November 14th.

Sangamo Therapeutics Trading Down 4.1 %

Shares of NASDAQ SGMO traded down $0.08 during midday trading on Friday, hitting $1.88. The company's stock had a trading volume of 5,345,239 shares, compared to its average volume of 10,465,058. Sangamo Therapeutics, Inc. has a 12-month low of $0.30 and a 12-month high of $3.18. The firm has a market cap of $392.26 million, a P/E ratio of -2.51 and a beta of 1.10. The business's 50 day moving average is $1.43 and its two-hundred day moving average is $0.91.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The business had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter last year, the firm posted ($0.34) earnings per share. On average, analysts predict that Sangamo Therapeutics, Inc. will post -0.52 earnings per share for the current fiscal year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.